trastuzumab,pertuzumab
roche
['phergain']
great presentation from dr cortes at #asco23 covering the #phergain results, exploring possibility of ct-free therapy in pts w/ her2+ #ebc. pet-based, pcr-adapted strategy was associated w/ 3-yr idfs benefits. identifies 1/3 pts who can omit ct w/ significantly toxicity 
COR2ED bringing you Independent Medical Education developed by BREAST CANCER CONNECT, international experts in Breast Cancer.